Abstract
A lower than normal function of the sympathetic nervous system (SNS) has been identified early in the course of multiple sclerosis (MS) and has been shown to play a role in the pathology of the disease. In addition, the chronic use of many drugs commonly used by MS patients could further downregulate SNS by interfering with norepinephrine (NE) synthesis/release and/or interfering with the function of the adrenergic receptors in both the brain and in the periphery. This drug-induced downregulation of SNS activity, when imposed on a background of SNS dysfunction, could not only promote immune inflammatory and neurodegenerative processes, but also can lead to a reduced clinical response to immunomodulaory therapies. Furthermore, low SNS activity could contribute to a higher prevalence of disorders such as depression, fatigue and osteoporosis, which has been observed in MS patients. An algorithm could be constructed based on the combination of baseline NE plasma levels and SNS response levels to a β-adrenergic agonist stimulus. This algorithm, corrected for age and gender, would have the potential to identify MS patients who have a reduced response to immunomodulatory therapies.
Keywords: Antidepressants, Antihypertensive, Antiplatelets, Autonomic dysfunction, Benzodiazepines, Multiple sclerosis, Noradrenergic receptors, Spasticity, Statins, drug-induced downregulation
Current Pharmaceutical Design
Title:Sympathetic Nervous System Dysfunction in Multiple Sclerosis, Linking Neurodegeneration to a Reduced Response to Therapy
Volume: 18 Issue: 12
Author(s): Zohara Sternberg
Affiliation:
Keywords: Antidepressants, Antihypertensive, Antiplatelets, Autonomic dysfunction, Benzodiazepines, Multiple sclerosis, Noradrenergic receptors, Spasticity, Statins, drug-induced downregulation
Abstract: A lower than normal function of the sympathetic nervous system (SNS) has been identified early in the course of multiple sclerosis (MS) and has been shown to play a role in the pathology of the disease. In addition, the chronic use of many drugs commonly used by MS patients could further downregulate SNS by interfering with norepinephrine (NE) synthesis/release and/or interfering with the function of the adrenergic receptors in both the brain and in the periphery. This drug-induced downregulation of SNS activity, when imposed on a background of SNS dysfunction, could not only promote immune inflammatory and neurodegenerative processes, but also can lead to a reduced clinical response to immunomodulaory therapies. Furthermore, low SNS activity could contribute to a higher prevalence of disorders such as depression, fatigue and osteoporosis, which has been observed in MS patients. An algorithm could be constructed based on the combination of baseline NE plasma levels and SNS response levels to a β-adrenergic agonist stimulus. This algorithm, corrected for age and gender, would have the potential to identify MS patients who have a reduced response to immunomodulatory therapies.
Export Options
About this article
Cite this article as:
Zohara Sternberg , Sympathetic Nervous System Dysfunction in Multiple Sclerosis, Linking Neurodegeneration to a Reduced Response to Therapy , Current Pharmaceutical Design 2012; 18 (12) . https://dx.doi.org/10.2174/138161212799958639
DOI https://dx.doi.org/10.2174/138161212799958639 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dynamic Changes in the Proteomic Profile of Mesial Temporal Lobe Epilepsy at Different Disease Stages in an Immature Rat Model
Protein & Peptide Letters Voltage-Gated Calcium Channels as Targets for the Treatment of Chronic Pain
Current Drug Targets - CNS & Neurological Disorders The Synthesis and Evaluation of Novel Lactate Dehydrogenase Nanobioconjugates
Current Nanoscience Nutrition and Bone Health: Its Relationship to Osteoporosis
Current Nutrition & Food Science NADPH Oxidase and Neurodegeneration
Current Neuropharmacology GABA Receptors: Pharmacological Potential and Pitfalls
Current Pharmaceutical Design Quinoline Derivatives: Candidate Drugs for a Class B G-Protein Coupled Receptor, the Calcitonin Gene-Related Peptide Receptor, a Cause of Migraines
CNS & Neurological Disorders - Drug Targets Substrates for Improved Live-Cell Fluorescence Labeling of SNAP-tag
Current Pharmaceutical Design Serotonergic System and Its Role in Epilepsy and Neuropathic Pain Treatment: A Review Based on Receptor Ligands
Current Pharmaceutical Design Conference Report: 10th International Summer School of Neurology: Celebrating a Decade of Success: 5th July, 2015 – 9th July, 2015 | Eforie Nord, Romania
CNS & Neurological Disorders - Drug Targets Characterization of the Early CNS Stress Biomarkers and Profiles Associated with Neuropsychiatric Diseases
Current Genomics Efficient High-throughput Techniques for the Analysis of Disease- Resistant Plant Varieties and Detection of Food Adulteration
Current Protein & Peptide Science The Plastic Phenomenon Underlying the Associative Processes in the Addictive Properties of Diazepam and Other Psychoactive Drugs
Mini-Reviews in Medicinal Chemistry Gender Medicine and Pharmacoeconomics: A Narrative Review of the International Literature of the Last 5 Years. A Revision of Evidences about the Relationship Between Gender and Economic Consumption in Health
Current Pharmaceutical Design Neuroimaging of Cancer Patients for Psychosocial Support and Patient Care
Current Medical Imaging Probiotics/Prebiotics in Viral Respiratory Infections: Implication for Emerging Pathogens
Recent Patents on Biotechnology Nerolidol and its Pharmacological Application in Treating Neurodegenerative Diseases: A Review
Recent Patents on Biotechnology Molecular Cytogenetics and Cytogenomics of Brain Diseases
Current Genomics Intracranial Cerebrospinal Fluid Volume Evaluation in Healthy People and Hydrocephalus Patients using SPACE Sequence
Current Medical Imaging University of Kentucky Sanders-Brown Healthy Brain Aging Volunteers: Donor Characteristics, Procedures and Neuropathology
Current Alzheimer Research